Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact
Core Evidence, 08/14/09
Krzesinski J–M et al. – The amlodipine/valsartan combination is an association of two well–known antihypertensive products with specific targets in cardiovascular protection, namely calcium channel blockade and antagonism of the renin–angiotensin–aldosterone system. This kind of association, with neutral metabolic properties and significant antihypertensive efficacy, could be a useful new antihypertensive product. Currently available data have shown that this new combination is well–tolerated and effective even in severe hypertension. Clinical trials are ongoing for further assessment of the efficacy, compliance, and safety of this combination and its congeners. No data exist to prove that the amlodipine/valsartan combination is better than other antihypertensive strategies for cardiovascular or renal protection, but some trials with other combination therapies show such potential advantage.
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Acute Coronary Syndromes: Diagnosis and Management, Part I
Mayo Clinic Proceedings, 10/05/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in older patients
Archives of Gerontology and Geriatrics, 10/13/09
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Acute Coronary Syndromes: Diagnosis and Management, Part I
Mayo Clinic Proceedings, 10/05/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in older patients
Archives of Gerontology and Geriatrics, 10/14/09
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Acute Coronary Syndromes: Diagnosis and Management, Part I
Mayo Clinic Proceedings, 10/05/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in older patients
Archives of Gerontology and Geriatrics, 10/13/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in General Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
Acute Coronary Syndromes: Diagnosis and Management, Part I
Mayo Clinic Proceedings, 10/05/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in General Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Acute Coronary Syndromes: Diagnosis and Management, Part I
Mayo Clinic Proceedings, 10/05/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/11/09
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/23/09
Current options for the treatment of resistant hypertension
Expert Review of Cardiovascular Therapy , 11/13/09
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/20/09
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension
Journal of Human Hypertension, 11/10/09
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/20/09
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension
Journal of Human Hypertension, 11/10/09
Article Search
Sponsor


See Latest Articles


